Although in most cases, there is a positive correlation between MYC-amplification and sensitivity to BETis, surprisingly, tumours lacking MYC amplification respond to the BETi treatment similarly to those with MYC amplification, suggesting that there are other targets within a cell for BETis [44,45,46]. The gene discussed is MYC; the disease is neoplasm.